Beta Bionics, Inc. Statistics
Want to see BBNX full AI Analyst Report?
Beta Bionics, Inc. (BBNX) Stock Statistics & Valuation Metrics
Total Valuation
Beta Bionics, Inc. has a market cap or net worth of $898.14M. The enterprise value is $649.16M.
- Market Cap
- $898.14M
- Enterprise Value
- $649.16M
Share Statistics
Beta Bionics, Inc. has 54,367,065 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 54,367,065
- Owned by Insiders
- 2.09%
- Owned by Institutions
- 30.82%
Financial Efficiency
Beta Bionics, Inc.’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -23.91%.
- Return on Equity (ROE)
- -0.25
- Return on Assets (ROA)
- -0.22
- Return on Invested Capital (ROIC)
- -23.91%
- Return on Capital Employed (ROCE)
- -0.24
- Revenue Per Employee
- 237.56K
- Profits Per Employee
- -173.46K
- Employee Count
- 422
- Asset Turnover
- 0.30
- Inventory Turnover
- 2.06
Valuation Ratios
The current PE Ratio of Beta Bionics, Inc. is -9.52. Beta Bionics, Inc.’s PEG ratio is 1.38.
- PE Ratio
- -9.52
- PS Ratio
- 6.30
- PB Ratio
- 2.07
- Price to FCF
- -12.15
- Price to Operating Cash Flow
- -13.96
- PEG Ratio
- 1.38
Income Statement
In the last 12 months, Beta Bionics, Inc. had revenue of 100.25M and earned -73.20M in profits. Earnings per share was -1.81.
- Revenue
- 100.25M
- Gross Profit
- 55.54M
- Operating Income
- -71.68M
- Pretax Income
- -73.20M
- Net Income
- -73.20M
- EBITDA
- -70.32M
- Earnings Per Share (EPS)
- -1.81
Cash Flow
In the last 12 months, operating cash flow was -59.37M and capital expenditures -6.59M, giving a free cash flow of -65.96M billion.
- Operating Cash Flow
- -59.37M
- Free Cash Flow
- -65.96M
- Free Cash Flow per Share
- -1.42
Dividends & Yields
Beta Bionics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.24%
- Earnings Yield
- -10.04%
Stock Price Statistics
- Beta
- 1.27
- 52-Week Price Change
- -38.20%
- 50-Day Moving Average
- 18.74
- 200-Day Moving Average
- 14.77
- Relative Strength Index (RSI)
- 50.96
- Average Volume (3m)
- 1.23M
Important Dates
Beta Bionics, Inc. upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 27, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
Beta Bionics, Inc. as a current ratio of 8.66, with Debt / Equity ratio of 2.54%
- Current Ratio
- 8.66
- Quick Ratio
- 7.96
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.35
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Beta Bionics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Beta Bionics, Inc. EV to EBITDA ratio is -8.71, with an EV/FCF ratio of -10.99.
- EV to Sales
- 5.70
- EV to EBITDA
- -8.71
- EV to Free Cash Flow
- -10.99
- EV to Operating Cash Flow
- -12.21
Balance Sheet
Beta Bionics, Inc. has $240.20M in cash and marketable securities with $6.10M in debt, giving a net cash position of $234.10M billion.
- Cash & Marketable Securities
- $240.20M
- Total Debt
- $6.10M
- Net Cash
- $234.10M
- Net Cash Per Share
- $4.31
- Tangible Book Value Per Share
- $8.62
Margins
Gross margin is 58.63%, with operating margin of -72.75%, and net profit margin of -65.31%.
- Gross Margin
- 58.63%
- Operating Margin
- -72.75%
- Pretax Margin
- -65.31%
- Net Profit Margin
- -65.31%
- EBITDA Margin
- -65.38%
- EBIT Margin
- -68.79%
Analyst Forecast
The average price target for Beta Bionics, Inc. is $24.83, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $24.83
- Price Target Upside
- 39.43% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 13
- Revenue Growth Forecast
- 43.69%
- EPS Growth Forecast
- -3.00%
Scores
- Smart Score
- 1
- AI Score
- 59
